361203-06-7

Upstream product

• 78423-10-6 1-(4-methoxyphenyl)-2-phenylbutan-1-one 
• 100-66-3 methoxybenzene 
• 36854-57-6 2-Phenylbutyryl chloride 
• 1371574-24-1 (E)-3-{4-[(E/Z)-1-(4-methoxyphenyl)-2-phenylbut-1-enyl]phenyl}acrylic acid 
• 850005-37-7 (E)-3-{4-[(Z)-1-(4-methoxyphenyl)-2-phenylbut-1-enyl]phenyl}acrylic acid 

Downstream Products

• 850005-45-7 (2E)-3-[4-((1Z)-1-{4-[(chloroacetyl)oxy]phenyl}-2-phenylbut-1-enyl)phenyl]prop-2-enoic acid 
• 850005-44-6 tert-butyl(dimethyl)silyl(2E)-3-{4-[(1Z)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenyl}-2-propenoate 

Relevant academic research and scientific papers

Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators

Up to 80% of mammary carcinoma initially exhibit estrogen-dependent growth, which can be treated by aromatase inhibitors or SERMs/SERDs. To increase the options after failure of the hormonal therapy with these drugs, the search for alternatives with a dif

Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity

Estrogen receptor α (ERα) is an important target for the design of drugs such as tamoxifen (2a) and fulvestrant (5). Three series of ER-ligands based on the benzoxepin scaffold structure were synthesized: series I containing an acrylic acid, series II with an acrylamide, and series III with a saturated carboxylic acid substituent. These compounds were shown to be high affinity ligands for the ER with nanomolar IC50 binding values. Series I acrylic acid ligands were generally ERα selective. In particular, compound 13e featuring a phenylpenta-2,4-dienoic acid substituent was shown to be antiproliferative and downregulated ERα and ERβ expression in MCF-7 breast cancer cells. Interestingly, from series III, the phenoxybutyric acid derivative compound 22 was not antiproliferative and selectively downregulated ERβ. A docking study of the benzoxepin ligands was undertaken. Compound 13e is a promising lead for development as a clinically relevant SERD, while compound 22 will be a useful experimental probe for helping to elucidate the role of ERβ in cancer cells.

NOVEL COMPOUNDS

The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel prodrugs that are particularly useful for delivering a parent compound for selective estrogen receptor modulation.